How to know which trial is best for your patient - BTOG National Trials Meeting 2026

Approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 5 category 1 (external) CPD credits (code: 155739)

Wednesday 22nd July 2026 - Cavendish Conference Centre, Duchess Mews, London

Programme

08:30	**Registration and Refreshments**	Whittington Suite
08:55	Welcome	Sanjay Popat
	Session 1: Treatment Landscape and Trial Strategies	**Chair: Tom Newsom-Davis**
09:00	Metastatic EGFR mutant NSCLC	Raffaele Califano
09:15	Metastatic KRAS mutant NSCLC	Anna Minchom
09:30	ADC-based treatments in metastatic NSCLC	Gary Middleton
09:45	Extensive stage small cell lung cancer	Fiona Blackhall
10:00	Mesothelioma	Sanjay Popat
10:15	**Panel Discussion**	Faculty
10:40	**Refreshments & Exhibition**	Whittington Suite
	Session 2: Delivering UK Research	**Chair: Cindy Billingham**
11:10	Is neoadjuvant immunotherapy enough for operable AGA- NSCLC?	Igor Randulfe
11:25	Moving the needle in LCNEC, is a UK trial possible?	Colin Lindsay
11:40	CONCORDE 2 - are we ready for take-off?	Alastair Greystoke
11:55	Local treatment in metastatic NSCLC: consolidation or whack a mole?	David Woolf
12:10	Treating rare cancers: DETERMINE and Target National	Matthew Krebs
12:25	MRD-based treatment in NSCLC: ready for prime time?	Crispin Hiley
12:40	**Panel Discussion**	Faculty + Allan Hackshaw
13:00	**Networking Lunch & Exhibition**	Whittington Suite
13:00	**Medical Trainee Meeting Point**	Whittington Suite
13:00	**Research Delivery Team Meeting Point**	Whittington Suite
	Session 3: Industry-Led Session	**Chair: Jason Adhikaree**
13:45	BioNTech	Belinda Kingston
14:00	Roche	Adam Januszewski (Pre-recorded)
14:15	Lilly	Sanjay Popat
14:30	**Refreshments & Exhibition**	Whittington Suite
	Session 4: Industry-Led Session	**Chair: Joanne Evans**
15:00	MSD	Louise Lim
15:15	Boehringer Ingelheim	Michael Davidson
15:30	AstraZeneca	Alastair Greystoke
15:45	Closing Remarks	Sanjay Popat
16:00	**Close**	

The BTOG National Trials Meeting is kindly sponsored by

Please note that, with the exception of Sessions 3 and 4, sponsors have not been involved or influenced the content or agenda of this or any other BTOG education.

Sponsors have solely provided financial sponsorship, and sponsors have not been involved or influenced the content or agenda in Session 1 & 2. Sessions delivered with input from the sponsors are clearly marked in the programme. Please note that the presentations in Session 3 & 4 are provided in response to specific requests from the BTOG steering committee and they may contain pre-licence information and is non-promotional. The aim of the session is to provide an overview on clinical trials led by the pharmaceutical industry. Although these are commercial trials, the content is non-promotional and does not constitute pre-license promotion by the pharmaceutical industry.

About the Faculty

Jason Adhikaree – Member, BTOG Steering Committee. Jason graduated from Imperial College London in 2008 with MBBS and BSc (Hons) in Neuroscience. He completed junior doctor training in London and East Midlands. Previously held NIHR Academic Clinical Fellowship from ST3 and subsequently a MRC Clinical research training fellowship, completing a PhD in 2019. Jason is Honorary Consultant Medical Oncologist at Nottingham University Hospitals and a Clinical Associate Professor at the University of Nottingham.

Cindy Billingham – Member, BTOG Research Group. Lucinda Billingham BSc MSc PhD Cstat is Professor of Biostatistics at the University of Birmingham. She has worked for over 25 years as a Biostatistician at their Cancer Research UK Clinical Trials Unit and is now Director of Biostatistics for the unit working with a large team of Biostatisticians on an extensive portfolio of early and late phase trials. Lucinda has a special interest in lung cancer research and is the Chief Biostatistician for the National Lung Matrix Trial. As well as her PhD research on statistical methods for the simultaneous analysis of quality of life and survival data, other key areas of expertise include application of Bayesian methods in trials, design and analysis of trials in rare cancers, early phase trial design and statistical methodology for biomarker discovery, validation and evaluation for stratified medicine. She lectures on a number of undergraduate and postgraduate courses at Birmingham, teaches widely on external courses and provides PhD supervision.

Fiona Blackhall - Member, BTOG Research Group. Professor Fiona Blackhall is a consultant medical oncologist and director of the research and innovation division at The Christie, and professor of thoracic oncology at The University of Manchester. In 1997, Professor Blackhall was awarded a Cancer Research Campaign PhD Fellowship for a clinician in the field of angiogenesis and in collaboration with Judah Folkman. In 2001, she undertook a clinical and post-doctoral fellowship at Princess Margaret Hospital and Ontario Cancer Institute in molecular pathology of lung cancer, biomarkers and drug development. Professor Blackhall is the clinical translational and biomarkers theme lead for the Cancer Research UK Lung Cancer Centre of Excellence. She has served as clinical lead of the Greater Manchester Cancer Genomics Pathway Board, clinical cancer lead of the North West NHS Genomics Laboratory Hub, NIHR GM Clinical Research Network Lung cancer lead, chair of the Advanced Disease Subgroup of the UK NCRI Lung Cancer Research Group, and co-chair of the Translational Subgroup of the European Thoracic Oncology Platform. She has been a faculty member for The European Society of Medical Oncology, The European Lung Cancer Conference, The American Society of Medical Oncology Annual Meeting and The International Association for the Study of Lung Cancer. In Manchester, since 2005, Professor Blackhall has created an environment for research spanning lung cancer biology, liquid biomarkers, novel therapies, phase I-III clinical trials, radiotherapy and supportive care with over 250 publications in these areas. She has collaborated with Professor Caroline Dive since 2007 on internationally leading research in circulating tumour cells. In 2020, Professor Blackhall received The ESMO/IASLC Heine H. Hansen Award which recognises outstanding contribution to lung cancer research and education. In 2021, she was appointed to director of the research and innovation division at The Christie to bring a strategy of operational transformation to accelerate access to an inclusive research portfolio. She is an advocate of team science and has enjoyed numerous collaborations with like-minded colleagues across the globe with the collective aim to make lung cancer a less deadly disease.

Raffaele Califano - Professor Raffaele Califano graduated in Medicine and Surgery, summa cum laude, from the University of Perugia, Italy, in 2003 and completed his specialist training in Medical Oncology, summa cum laude, in 2007. He then worked as Clinical Research Fellow with the lung and melanoma team at The Christie, being an investigator for several clinical trials in lung cancer and melanoma and developing a particular interest in molecularly driven clinical trials in lung cancer. Prof Califano has been a consultant at The Christie and Manchester University Hospital since 2012 and specialises in the treatment of thoracic malignancies. He has led on several practice-changing clinical trials for lung cancer and mesothelioma. Prof Califano is the author of several papers published in indexed peer-reviewed international journals and he has been an invited speaker to several national and international oncology meetings.

Michael Davidson is Consultant Medical Oncologist at Royal Marsden NHS Foundation Trust.

Joanne Evans is a consultant in medical oncology at Imperial College Healthcare NHS Trust where she specialises in the treatment of all thoracic malignancies and as a cancer generalist, providing 'acute oncology' services. She holds an Honorary Senior Teaching Fellowship at the Institute of Cancer Research and an Honorary Senior Lectureship at Imperial College London. A basic medical scientist by initial training, holding a first degree in genetics and a molecular biology-based DPhil, both awarded before reading medicine, with the intension of becoming an oncologist. Her area of expertise as a molecular oncologist lies in lung cancers harbouring 'driver mutations'; including EGFR, ALK, BRAF V600, MET exon 14 skip, RET, NTRK, ROS1 and KRAS G12C mutations. She also has considerable expertise in delivering combination therapies across cytotoxic chemotherapy, immunotherapy and tyrosine kinase inhibitors across non-small cell lung cancers, small cell lung cancers, mesothelioma and thymic epithelial malignancies. She has especially enjoying growing the lung themed clinical trials portfolio at the Trust and has acted in the capacity of both local principle investigator, and chief investigator on both national and international trials. She also enjoys and values participating in research, working closely with several academic research groups, presenting work nationally and internationally. She also serves on the Scientific Advisory Board of ALK Positive. She enjoys teaching and contributes to both undergraduate and postgraduate medical curriculum delivery. She is the lung cancer module lead for the Institute of Cancer Research's MSc in oncology and has been an invited speaker for organisations such as Royal College of Physicians, Edinburgh, Royal College of Physicians, England and the British Thoracic Oncology Society.

Alastair Greystoke - Member, BTOG Research Group and BTOG Steering Committee. Professor Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 4 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies. In addition, he is the Clinical Director for Cancer for the Yorkshire, Hull and Northeast England Genomic Medicine Service and led the NHSE pilot assessing the cost-effectiveness of cfDNA in patients presenting with advanced lung cancer. He is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer) and leads the Pharmacodynamic Biomarker team at Newcastle University Cancer.

Allan Hackshaw - Member, BTOG Research Group. Allan is Professor is Director of Cancer Research UK and University College London, CRUK Cancer Trials Centre. Allan is a former member of the BTOG Steering Committee and a current member of the BTOG Research Group. Allan has worked in medical research since 1992. He has substantial experience in a variety of disease areas, including cancer treatments and diagnosis, cardiovascular disease, genetic and structural disorders during pregnancy, and tobacco and health. He has worked in several cancer types (notably lung, thyroid, and gynaecological) and all types of interventions (systematic therapies including targeted and immunotherapies, advanced cell/gene therapies, radiotherapy, surgery, and combinations of them). His special interest is in adult and prenatal screening. He is Vice-Chair of the UK National Screening Committee Adult Reference Group, and co-editor of the Journal of Medical Screening. Several of the large-scale studies for which he has been a key investigator has changed national and international clinical or public health screening practice. He has been a key co-investigator on successful grant funding applications (>£150 million in total), published more than 250 journal articles and book chapters, and sole or first author of five textbooks including 'A Concise Guide to Clinical Trials' 2024, 'A Concise Guide to Observational Studies' 2015 and 'How to write a grant application' 2011, all from Wiley/Blackwells, and 'Fast Facts: clinical trials in oncology' from Karger 2020. He has comprehensive knowledge of conducting multicentre clinical studies (small and large scale), including regulations and other decision-making processes.

Crispin Hiley - Member, BTOG Research Group. Dr Hiley is an Associate Professor with tenure in Radiation Oncology at UCL and an Honorary Consultant Clinical Oncologist at UCLH. He graduated with honours from the University in Manchester in 2005. He has trained in Oncology at many centres of excellence both in the UK and aboard. These include the Christie Hospital, the MD Anderson Cancer Centre (Houston, USA), Kings College (NIHR Clinical Lecturer) and the Royal Marsden (NIHR Clinical Fellow). He completed a PhD at the University of London with the Barts Cancer Institute and a postdoctoral research Fellowship the Francis Crick Institute and the UCL Cancer institute. He became a consultant in 2018 joining the thoracic oncology team at UCLH. In addition, he is the UCLH Lead for Lung Proton Therapy, Deputy Lead of Clinical Trials Theme for the CRUK Lung Cancer Centre of Excellence and NIHR Clinical Research Network Speciality Research Lead Radiotherapy for North London. He heads a research group at the UCL Cancer Institute focused on understanding resistance to radiation therapy. Dr Hiley specialises in non-surgical treatments for all types of lung cancer. He has expertise in chemotherapy, immunotherapy and radiotherapy including state of the art radiotherapy techniques including Volumetric Arc Therapy (VMAT), Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Proton Therapy and Stereotactic Radiotherapy (SBRT). Dr Hiley has expertise in treating all sites of metastatic disease (except for brain) with stereotactic radiotherapy including lung, liver, lymph nodes, adrenal glands, spine and other bone sties. He is the principal investigator and national chief investigator for several academic and commercial clinical trials in lung cancer. He has published in several the world's leading journals including NEJM, The Lancet, Nature and Cell. He is a member of the expert group which authored the Radiotherapy for Lung Cancer Royal College of Radiologists Consensus Statement.

Adam Januszewski, PhD MRCP is Consultant Medical Oncologist and Quality and Safety Lead at Barts Cancer Centre.

Belinda Kingston - Country Clinical, Associate Director at BioNTech UK Ltd.

Matthew Krebs - Clinical Senior Lecturer at Cancer Research UK, Manchester. Matt is also an Honorary Consultant in Medical Oncology at The Christie Dr Krebs completed his Medical undergraduate training at the University of Leicester in 2001 and general medical training in Manchester in 2005. He specialty trained in Medical Oncology at The Christie NHS Foundation Trust, was awarded a PhD in circulating biomarkers with application to drug development in 2011 and completed training as an academic clinical lecturer with post-doctoral experience in single cell molecular profiling. Dr Krebs was appointed to his current position as Clinical Senior Lecturer in Experimental Cancer Medicine in 2014. He undertakes early-phase clinical trials with interests in drug development for lung cancer and precision medicine. His translational research focuses on the clinical application of circulating tumour DNA to guide personalised treatment selection and to monitor treatment response and resistance. He has been Principal or Chief Investigator on >40 and co-investigator on >75 early phase clinical trials across a broad range of novel therapies. He is lead for Precision Medicine within the Experimental Cancer Medicine Team, Chief Investigator of the TARGET Precision Medicine program, Chair of the Manchester Molecular Tumour Board and co-theme lead for Clinical Trials within the CRUK Manchester-UCL Lung Cancer Centre of Excellence.

Colin Lindsay - Member, BTOG Research Group. Dr. Colin Lindsay is a Clinical Senior Lecturer in Medical Oncology at The Christie NHS Foundation Trust, balancing his time between transformative research and dedicated patient care. His journey began at the CRUK Beatson Institute in Glasgow, where he earned his PhD under Owen Sansom, investigating genetically modified mouse models of RAS and RAF-driven melanoma.
Transitioning to lung cancer translation, Colin engaged with the CRUK Stratified Medicine Programme and pursued a two-year ESMO translational fellowship at the Gustave Roussy Institute in Villejuif, France, under Benjamin Besse and Jean-Charles Soria. Colin's primary research focus is on implementing effective treatment strategies for RAS-driven cancers and translating genomic results for optimal clinical impact. In his role, Colin treats non-small cell lung cancer and small cell lung cancer, participates in NHS clinics and ward rounds, and leads as a principal and co-investigator for phase II and III clinical trials.

Louise Lim is Consultant Medical Oncologist at Barts Health NHS Trust.

Gary Middleton - Member, BTOG Research Group. Gary Middleton is Professor of Medical Oncology in the Department of Immunology and Immunotherapy, Honorary Consultant Oncologist at University Hospitals Birmingham and Director of the Birmingham Experimental Cancer Medicine Centre (ECMC). He drives the translation of Birmingham cancer immunology and genomics science into novel clinical research, collaboratively delivered across the ECMC network. Committed to developing a vibrant next generation of academic oncologists, Gary directs the Birmingham CRUK Clinical Academic Training Programme.

Anna Minchom - Member, BTOG Research Group. Dr Anna Minchom is a Consultant Medical Oncologist and BRC Clinical Scientist in the Drug Development Unit at the Royal Marsden Hospital and the Institute of Cancer Research, and the Lung Unit at the Royal Marsden Hospital. Dr Minchom completed her undergraduate medical training in the University of Wales College of Medicine, qualifying in 2003. She was awarded MRCP in 2008. She trained in medical oncology at the Royal Marsden Hospital during which time she completed laboratory research investigating mechanisms of resistance to targeted drugs in non-small cell lung cancer, for which she was awarded an MD(res). Dr Minchom is principal investigator on early phase drug trials including first-in-human clinical trials. Her main research focus is using a biomarker-driven and translational approach to develop novel drugs and drug combinations for the treatment of patients with lung cancer and mesothelioma.

Tom Newsom-Davis – Chair, BTOG Steering Committee. Tom is a consultant thoracic medical oncologist at Chelsea and Westminster Hospital, London. He has an active clinical trials portfolio. He has been UK Chief Investigator for a number of studies, as well as chairing Independent Data Monitoring Committees and sitting on trial steering groups. He has published over 70 papers and presented more than 120 abstracts in national and international meetings. Tom joined the steering committee of BTOG in 2017. He serves on the Multidisciplinary Clinical Science Committee of the International Association for the Study of Lung Cancer (IASLC), on the Oncology Council of the Royal Society of Medicine, and as an invited clinic expert for NICE. Tom is past Chair of the RM Partners Cancer Alliance Lung group, and past member of the NCRI Lung Cancer Clinical Studies Group. Tom has been an invited lecturer for various organisations including the Royal College of Physicians, European Society of Medical Oncology (ESMO), IASLC, British Medical Association and the Association of Cancer Physicians. He has been a faculty member for ESMO and IASLC meeting. His work on Acute Diagnostic Oncology Clinics has previously been awarded a Macmillan Innovation Excellence Award.

Sanjay Popat – Chair, BTOG Research Group is Consultant Medical Oncologist and Head of the Lung Unit BSc MBBS FRCP PhD at Royal Marsden NHS Foundation Trust. Professor Popat qualified in Medicine (MBBS) from the University of London in 1994 with triple distinction, a 1st class BSc in Experimental Pathology, and the Solly undergraduate Medal in Medicine. He went on to receive his PhD in the field of molecular genetics from the University of London in 2002 and then undertook a post-doctoral fellowship in somatic genomics during his medical oncology training. He was appointed consultant medical oncologist to the Royal Marsden Hospital in 2007 where he is now Head of the Lung Unit and Head of Lung Research. In 2019, he was appointed Professor of Thoracic Oncology at the Institute of Cancer Research. His research interests include lung cancer in never smokers, the optimization and implementation of genomics into routine clinical practice and the development of novel therapeutics through clinical trials. He has published over 300 peer-review manuscripts with over 20,000 citations, including influential trial manuscripts in oncogene-addicted NSCLC and mesothelioma leading to global licensing, reimbursement in multiple territories, and guidelines adoption. From 2023 he co-led the NHS England implementation programme of ctDNA NGS for lung cancer, leading to national ctDNA reimbursement in 2025. He has a solid understanding of research governance with drug regulatory experience as clinical expert with EMA and reimbursement experience as clinical expert to NICE for multiple submissions. Alongside original research outputs, he has led or co-authored multiple ESMO clinical guidelines including the Clinical Practice Guidelines for advanced NSCLC, extensive stage SCLC, and mesothelioma, alongside ESMO Expert Consensus Statements, and authored British guidelines for the BMJ and the British Thoracic Society. He has considerable experience in working for National and International Agencies. In the UK, he was British Thoracic Oncology Group (BTOG) Steering Committee Chair for 13 years and currently chairs the BTOG Research Group. He was Cancer Division co-chair of the UK NIHR London South Clinical Research Network, is past Chair of the UK NCRI Lung Group Advanced Disease sub-group and currently Chairs the West London Genomic Tumour Advisory Board. Internationally, he has served for ESMO as Scientific Faculty, or Chair of Lung Tracks at several ESMO Annual Meetings, ESMO Asia, and other ESMO educational meetings. He also sits on the ETOP-IBCSG Partners Foundation Council and its Scientific Committee, where he has Co-Chaired multiple international academic studies. He is active in the IASLC, serving as Track Chair or Scientific Faculty for several WCLC Congresses and other IASLC meetings, and serves on their Rare Diseases committee.

Igor Randulfe - Member, BTOG Research Group**.** Igor graduated in Medicine and Surgery from the University of Santiago de Compostela, Galicia, in 2016 and completed his specialist training in Medical Oncology at University Hospital A Coruña in 2022. He then worked as a Consultant in Medical Oncology at University Hospital A Coruña before moving to Manchester in 2023 to join The Christie as a Senior Clinical Research Fellow with the lung cancer team. Dr Randulfe is a Consultant in Medical Oncology at The Christie, specialising in the treatment of thoracic malignancies, including non-small cell lung cancer and small cell lung cancer. He is actively involved in lung cancer research and clinical trials. He has been a Principal Investigator and Sub-Investigator in a number of clinical trials and observational studies, with a particular interest in immunotherapy, small cell lung cancer, real-world outcomes and improving access to clinical trials for patients with thoracic cancers. Dr Randulfe is the author of several papers published in indexed, peer-reviewed international journals and has been invited to speak at national and international oncology meetings.

David Woolf is Consultant Clinical Oncologist at the Christie NHS Foundation Trust. Dr Woolf is a graduate of the University of Birmingham. Core medical and Clinical Oncology training was in London (University College Hospital, The Royal Free and St Bartholomews'). A master's degree in Oncology at the Institute of Cancer Research and a Doctorate of Medicine after research at Mount Vernon Cancer Centre. Dr Woolf has a particular interest in the development of high-quality health care participating as a member of the Keogh Quality of Care Review Inspections Panel and as Clinical Expert in Care Quality Commission (CQC) inspections. Over 20 publications in peer reviewed journals and published book chapters as well as over 40 oral and poster presentations to national and international conferences. These include multiple publications and presentations in the field of breast and lung cancer. Particular interest in using imaging techniques (scans) to assess response to treatment. Developed the RESPECT study assessing the response of patients with bone metastasis to treatment using Whole Body MRI scans. Member of European Organisation for Research and Treatment of Cancer (EORTC) bony metastatic working group.